News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genentech (RHHBY) Says Blood Cancer Drug Met Stage One Goal


1/31/2013 7:56:02 AM

Roche's GA101 drug significantly improved progression-free survival in people with chronic lymphocytic leukaemia (CLL), giving the Swiss drugmaker the first signal it may have a viable successor to its current best-selling medicine. Roche is banking on the success of GA101 to fend off the threat of so-called biosimilar copies of cancer treatment MabThera, its top seller in 2012 with sales of 6.7 billion Swiss francs ($7.3 billion). Roche said on Thursday data from the first late-stage study on GA101 found taking the drug together with chlorambucil, a chemotherapy, significantly reduced the risk of the disease worsening or death compared with chlorambucil alone. A second set of data specifically comparing GA101 with MabThera, also known as Rituxan, is due later this year. Daniel O'Day, head of Roche pharmaceuticals had told analysts at a results presentation on Wednesday that Roche was awaiting the results of several studies "to get confidence that this has the potential to give us a significant advantage on MabThera".

Read at Reuters
Read at Fox News
Read at Bloomberg
Read at Wall Street Journal


comments powered by Disqus
Genentech
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES